KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Net Margin (2016 - 2025)

Rigel Pharmaceuticals has reported Net Margin over the past 15 years, most recently at 384.04% for Q4 2025.

  • For Q4 2025, Net Margin rose 35914.0% year-over-year to 384.04%; the TTM value through Dec 2025 reached 124.72%, up 11497.0%, while the annual FY2025 figure was 124.72%, 11497.0% up from the prior year.
  • Net Margin for Q4 2025 was 384.04% at Rigel Pharmaceuticals, up from 40.17% in the prior quarter.
  • Over five years, Net Margin peaked at 384.04% in Q4 2025 and troughed at 164.0% in Q1 2022.
  • A 5-year average of 3.86% and a median of 11.51% in 2023 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: plummeted -21275bps in 2022 and later surged 35914bps in 2025.
  • Year by year, Net Margin stood at 110.76% in 2021, then skyrocketed by 102bps to 2.73% in 2022, then dropped by -25bps to 2.06% in 2023, then skyrocketed by 1109bps to 24.9% in 2024, then surged by 1442bps to 384.04% in 2025.
  • Business Quant data shows Net Margin for RIGL at 384.04% in Q4 2025, 40.17% in Q3 2025, and 58.63% in Q2 2025.